Dr. Antonarakis on the Benefits of Genetic Testing for Select Patients With Prostate Cancer
Emmanuel Antonarakis, MD, discusses the benefits of somatic and germline testing for patients with prostate cancer.
Dr. Antonarakis on Therapeutic Agents for Select Patients With mCRPC
Emmanuel Antonarakis, MD, discusses the different therapeutic agents that are available for patients with metastatic castration-resistant prostate cancer who display either somatic or germline mutations.
Dr. Antonarakis on Implications of an MMR Deficiency in Prostate Cancer
Emmanuel S. Antonarakis, MD, associate professor of oncology, Johns Hopkins University, discusses the clinical implications of an MMR deficiency in patients with prostate cancer.
Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization
Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?
EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management
Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment
2 Commerce Drive Cranbury, NJ 08512